Shareprice
18 Apr 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

Investor presentations for FluoGuide in H2 2022

News


August 16, 2022

Copenhagen, Denmark, 16 August 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that Morten Albrechtsen, CEO of FluoGuide will present FluoGuide at the following Investor meetings in H2 2022:

  • 7-8 September, Pareto Securities 13th Annual Heath Care Conference, Stockholm
  • 15 September, Redeye Investor AW, Malmö
  • 26 October, Redeye theme event, Stockholm
  • 21-23 November, SEB Healthcare seminar, Stockholm
  • 24 November, Redeye Life Science Day, Stockholm

More information is available on https://fluoguide.com/investor/calendar-events/

For further information, please contact:

Morten Albrechtsen, CEO, FluoGuide A/S
+45 24 25 62 66,
ma@fluoguide.com

Certified Adviser:
Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51
E-mail: ca@skmg.se

About FluoGuide
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is has demonstrated efficacy of F001 as well as it to be well tolerated and safe in the ongoing proof-of-concept clinical study (phase I/II) in patients with high grade glioma undergoing surgery. FluoGuide has also started a phase II trial to demonstrate the effect of FG001 in guiding cancer surgery in patients with lung cancer. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.

For more information on the Company’s uPAR technology platform and our pipeline please visit our home page www.fluoguide.com

This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954904.